Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

March 9, 2018: By Joan McKenna

Okogen announced Feb. 27 that it raised $10 million in a Series A financing to advance OKG-0301, its lead candidate for viral conjunctivitis (pink eye).

The San Diego-based company describes OKG-0301 as an ophthalmic formulation of ranpirnase, a potent ribonuclease with established broad-spectrum antiviral properties.

Brian M. Strem, CEO, said the funding would support initiation of a Phase II clinical trial before the end of 2018.

The company’s focus is on infectious ocular diseases where treatments are either not available or unsatisfactory. A second targeted disease is cytomegalovirus retinitis.

Brandon Capital’s Medical Research Commercialisation Fund, a collaboration between Australian pension funds, research institutes, and the Australian and New Zealand governments, provided the funding.

Okogen also announced the appointment of Quinton Oswald to the firm’s board. Oswald is president and CEO of Notal Vision. Previously, he was president and CEO at Neurotech Pharmaceuticals and SARcode Bioscience. Oswald also held executive level roles at Genentech, Novartis, and Bristol-Myers Squibb.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Aerie Submits NDA for Roclatan to US FDA

Surface Raises $20 Million in Series A Financing from Flying L Partners

iSTAR Announces ‘Promising’ Early-Stage Results for MINIject MIGS Device

Carl Zeiss Meditec Revenues Total $723.8 Million in the First Half of FY2018, a 4.5 Percent Increase

Moorfields Team Develops Drink-Based Dye for Diagnosing Retinal Disease in Children

Supreme Court Upholds Inter Partes Review Process for Challenging Patents

Study Indicates Ophthalmology Residents Face High Burden of Burnout, Depression

Takeda Makes Firm $62.2 Billion Bid for Shire

Valeant to Rebrand as Bausch Health Companies in July

Hoya Receives CE Mark for Vivinex IOL with 4-in-1 MultiSert Preloaded Delivery System

Tilganga Institute of Ophthalmology Gets $930 Thousand Grant to Double IOL Production

Abpro Postpones $60 Million IPO; Company Has Anti-VEGF/ANG-2 Product Candidate

Valeant Reports Q1-2018 Revenues of $1.9 Billion, a Decline of 5 Percent

Glaukos’ Net Sales Grow 12 Percent in Q1-2018

Second Sight Reports 16 Argus II Implants in Q1-2018

Omeros’ Omidria Revenues Drop 86 Percent in Q1-2018; Company Attributes Decline to Temporary Loss of Pass-through Status

Bausch + Lomb Starts Clinical Trial for New Ophthalmic Viscosurgical Device

NEI Awards LayerBio $1.2 Million to Develop Sustained-Release Glaucoma Drug

Bausch + Lomb Launches Lumify, OTC Eye Drop with Low-Dose Brimonidine for Ocular Redness

Aerie Launches Rhopressa in US as Treatment for Lowering IOP

Coming soon

2018 Cataract Surgical Equipment Report: A Global Market Analysis for 2017 to 2023